Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients

Annals of Oncology

Volumn 16, Issue 10, 2005, Pages 1646-1653

  Westra, J L ^a   Hollema, H ^a   Schaapveld, M ^b   Platteel, I ^a   Oien, K A ^c   Keith, W N ^c   Mauritz, R ^d   Peters, G J ^d   Buys, C H C M ^a   Hofstra, R M W ^a   Plukker, J Th M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Integraal Kankercentrum Noord Nederland   (Netherlands)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Colon cancer; Dihydropyrimidine dehydrogenase; Prediction 5 fluorouracil regimen; Thymidylate synthase; TP53

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID; LEVAMISOLE; PROTEIN P53; THYMIDYLATE SYNTHASE;

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 27144456276     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi316     Document Type: Article

References (36)

1. Moertel CG, Fleming TR, MacDonald JS et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med 1995; 122: 321-326.
2. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345: 939-944.
3. Finedo HM, Peters GF. Fluorouracil: Biochemistry and pharmacology. J Clin Oncol 1988; 6: 1653-1664.
4. Aschele C, Lonardi S, Monfardini S. Thymidylate synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. Cancer Treat Rev 2002; 28: 27-47.
5. Lu ZH, Zhang R, Diasio RB. Purification and characterization of dihydropyrimidine dehydrogenase from human liver. J Biol Chem 1992; 267: 17102-17109.
6. Wright JE, Dreyfuss A, el-Magharbel I et al. Selective expansion of 5,10-methylenetetrahydrofolate pools and modulation of 5-fluorouracil antitumor activity by leucovorin in vivo. Cancer Res 1989; 49: 2592-2596.
7. Cho E, Takechi T, Jones KL et al. Thymidylate synthase binds to c-myc RNA in human colon cancer cells in vitro. Mol Cell Biol 1995; 15: 179-185.
8. Chu E, Copur SM, Ju J et al. Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex. Mol Cell Biol 1999; 96: 1582-1594.
9. Ju J, Pedersen-Lane J, Maley F, Chu E. Regulation of p53 expression by thymidylate synthase. Proc Natl Acad Sci USA 1999; 96: 3769-3774.
10. Johnston PG, Fisher ER, Rockette HE et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994; 12: 2640-2647.
11. Takenoue T, Nagawa H, Matsuda K et al. Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method. Ann Surg Oncol 2000; 7: 193-198.
12. Edler D, Glimelius B, Hallstrom M et al. Thymidylate synthase expression in colorectal cancer: A prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 2002; 20: 1721-1728.
13. Kornmann M, Schwabe W, Sander S et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: Predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 2003; 9: 4116-4124.
14. Yamachika T, Nakanishi H, Inada K et al. A new prognostic factor for colorectal carcinoma, thymidylate synthase and its therapeutic significance. Cancer 1998; 82: 70-77.
15. Tomiak A, Vincent M, Earle CC et al. Thymidylate synthase expression in stage II and III colon cancer: A retrospective review. Am J Clin Oncol 2001; 24: 597-602.
16. Nanni O, Volpi A, Frassineti GL et al. Role of biological markers in the clinical outcome of colon cancer. Br J Cancer 2002; 87: 868-875.
17. Paradiso A, Simone G, Petroni S et al. Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 2000; 82: 560-567.
18. Aschele C, Debernardis D, Tunesi G et al. Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Clin Cancer Res 2000; 6: 4797-4802.
19. Johnston PG, Benson 3rd AB, Catalano P et al. Thymidylate synthase protein expression in primary colorectal cancer: Lack of correlation with outcome and response to fluorouracil in metastatic disease sites. J Clin Oncol 2003; 21: 815-819.
20. Salonga D, Danenberg KD, Johnson M et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6: 1322-1327.
21. Tokunaga Y, Nakagami M, Tokuka A, Ohsumi K. Prognostic effects of dihydropyrimidine dehydrogenase in advanced colorectal cancer after surgery: Immunohistochemistry using a new monoclonal antibody. Anticancer Res 2003; 23: 1763-1768.
22. Tsuji T, Sawai T, Takeshita H et al. Tumor dihydropyrimidine dehydrogenase in stage II and III colorectal cancer: Low level expression is a beneficial marker in oral-adjuvant chemotherapy, but is also a predictor for poor prognosis in patients treated with curative surgery alone. Cancer Lett 2004; 204: 97-104.
23. Ichikawa W, Uetake H, Shirota Y et al. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 2003; 9: 786-791.
24. Kornmann M, Link KH, Galuba I et al. Association of time to recurrence with thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression in stage II and III colorectal cancer. J Gastrointest Surg 2002; 6: 331-337.
25. Ikeguchi M, Makino M, Kaibara N. Thymidine phosphorylase and dihydropyrimidine dehydrogenase activity in colorectal carcinoma and patients prognosis. Langenbecks Arch Surg 2002; 387: 240-245.
26. Lenz HJ, Hayashi K, Salonga D et al. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: An analysis of response and survival. Clin Cancer Res 1998; 4: 1243-1250.
27. Longley DB, Boyer J, Allen WL et al. The role of thymidylate synthase induction in modulating p53 regulated gene expression in response to 5-fluorouracil and antifolates. Cancer Res 2002; 62: 2644-2649.
28. Bleeker WA, Mulder NH, Hermans J et al. The addition of low-dose leucovorin to the combination of 5-fluorouracil-levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer. Ann Oncol 2000; 11: 547-552.
29. Sobin LH, Wittekind Ch (eds). UICC International Union Against Cancer TNM Classification of Malignant Tumors, 6th edition. New York: Wiley-Liss 2002.
30. Hayes VM, Bleeker W, Verlind E et al. Comprehensive TP53-denaturing gradient gel electrophoresis mutation detection assay also applicable to archival paraffin-embedded tissue. Diagn Mol Pathol 1999; 8: 2-10.
31. Hoos A, Cordon-Cardo C. Tissue microarray profiling of cancer specimens and cell lines: Opportunities and limitations. Lab Invest 2001; 81: 1331-1338.
32. Van Triest B, Loftus BM, Pinedo HM et al. Thymidylate synthase expression in patients with colorectal carcinoma using a polyclonal thymidylate synthase antibody in comparison to the TS 106 monoclonal antibody. J Histochem Cytochem 2000; 48: 755-760.
33. Huang CL, Yokomise H, Kobayashi S et al. Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy. Int J Oncol 2000; 17: 47-54.
34. Backus HH, Wouters D, Ferreira CG et al. Thymidylate synthase inhibition triggers apoptosis via caspases-8 and -9 in both wild-type and mutant p53 colon cancer cell lines. Eur J Cancer 2003; 39: 1310-1317.
35. Longley DB, Latif T, Boyer J et al. The interaction of thymidylate synthase expression with p53-regulated signaling pathways in tumor cells. Semin Oncol 2003; 30 (Suppl 6): 3-9.
36. Marsh S, McKay JA, Curran S et al. Primary colorectal tumour is not an accurate predictor of thymidylate synthase in lymph node metastasis. Oncol Rep 2002; 9: 231-234.